From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs.
暂无分享,去创建一个
[1] R. Burns,et al. Phencyclidine use among youth: history, epidemiology, and acute and chronic intoxication. , 1978, NIDA research monograph.
[2] G. Albers,et al. Safety, Tolerability, and Pharmacokinetics of the N-Methyl-d-Aspartate Antagonist Dextrorphan in Patients With Acute Stroke , 1995 .
[3] J. Ramsey,et al. Novel drugs--novel branding. , 2012, QJM : monthly journal of the Association of Physicians.
[4] M. Peet,et al. Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague–Dawley rats , 2010, Pharmacology Biochemistry and Behavior.
[5] K. Brady,et al. Discriminative stimulus properties of phencyclidine and five analogues in the squirrel monkey , 1981, Pharmacology Biochemistry and Behavior.
[6] M. Weller,et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. , 1994, Journal of neural transmission. Supplementum.
[7] M. Coppola,et al. Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics? , 2013, Medical hypotheses.
[8] M. Klein,et al. Abuse Liability Assessment of Neuroprotectants , 1999, Annals of the New York Academy of Sciences.
[9] Jeanine A Ward,et al. Methoxetamine: a novel ketamine analog and growing health-care concern , 2011, Clinical toxicology.
[10] M. Meyer,et al. Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn , 2013, Analytical and Bioanalytical Chemistry.
[11] J Robles,et al. PCP: a review of synthetic methods for forensic clandestine investigation. , 1993, Forensic science international.
[12] F. Hammerschmidt,et al. NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds. , 2009, Bioorganic & medicinal chemistry.
[13] F. Peters,et al. New designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. , 2008, Journal of mass spectrometry : JMS.
[14] O. Corazza,et al. From “Special K” to “Special M”: The Evolution of the Recreational Use of Ketamine and Methoxetamine , 2013, CNS neuroscience & therapeutics.
[15] V. Setola,et al. The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor , 2013, PloS one.
[16] TOXIC PSYCHOSIS DUE TO DEXTROMETHORPHAN , 1967 .
[17] T. Noguchi,et al. Determination of 1-(1-phenylcyclohexyl) pyrrolidine (PHP) in postmortem specimens: a case report. , 1979, Clinical toxicology.
[18] M. Coppola,et al. Methoxetamine: from drug of abuse to rapid-acting antidepressant. , 2012, Medical hypotheses.
[19] Mohler Jl. Abnormal tests don't change smoking habits. , 1980 .
[20] J. Olney,et al. Neuronal Vacuolization and Necrosis Induced by the Noncompetitive N-methyl-d-aspartate (NMDA) Antagonist MK(+)801 (Dizocilpine Maleate): A Light and Electron Microscopic Evaluation of the Rat Retrosplenial Cortex , 1993, Experimental Neurology.
[21] E. Cone,et al. Phencyclidine analogs and precursors: rotarod and lethal dose studies in the mouse. , 1984, The Journal of pharmacology and experimental therapeutics.
[22] J. Krystal,et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.
[23] C. Parsons,et al. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.
[24] R. Garey,et al. PCP (phencyclidine): an update. , 1979, Journal of psychedelic drugs.
[25] G. Chen,et al. The pharmacology of 1-(1-phenylcyclohexyl) piperidine-HCl. , 1959, The Journal of pharmacology and experimental therapeutics.
[26] L. Iversen,et al. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[27] P. Dargan,et al. Characterizing metabolites and potential metabolic pathways for the novel psychoactive substance methoxetamine. , 2014, Drug testing and analysis.
[28] K. Lees,et al. Clinical experience with excitatory amino acid antagonist drugs. , 1995, Stroke.
[29] D. Lodge,et al. Differential effects of dextrorphan and levorphanol on the excitation of rat spinal neurons by amino acids. , 1985, European journal of pharmacology.
[30] G. Chen,et al. The pharmacology of 2-(ethylamino)-2-(2-thienyl)-cyclohexanone-HCl (CI-634). , 1969, The Journal of pharmacology and experimental therapeutics.
[31] J. Olney,et al. Serotonergic Agents That Activate 5HT2A Receptors Prevent NMDA Antagonist Neurotoxicity , 1998, Neuropsychopharmacology.
[32] F. Vollenweider,et al. Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis , 1997, Neuropsychopharmacology.
[33] David R. Spiegel,et al. Psychosis Induced by the Interaction of Memantine and Amantadine: Lending Evidence to the Glutamatergic Theory of Schizophrenia , 2007 .
[34] V. H. Maddox,et al. THE SYNTHESIS OF PHENCYCLIDINE AND OTHER 1-ARYLCYCLOHEXYLAMINES. , 1965, Journal of medicinal chemistry.
[35] J. P. Morgan,et al. The dusting of America: the image of phencyclidine (PCP) in the popular media. , 1980, Journal of psychedelic drugs.
[36] R. Mcquinn,et al. Structure-activity relationship studies of phencyclidine derivatives in rats. , 1984, The Journal of pharmacology and experimental therapeutics.
[37] J. Wallach,et al. Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues. , 2014, Drug testing and analysis.
[38] J. Olney,et al. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. , 1989, Science.
[39] Tamara Hershey,et al. Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis , 1999, Neuropsychopharmacology.
[40] JOSEPH ZILBER,et al. issue 1 , 2020, JORDANIAN JOURNAL OF ENGINEERING AND CHEMICAL INDUSTRIES (JJECI).
[41] C. Man,et al. 'Street ketamine'-associated bladder dysfunction: a report of ten cases. , 2007, Hong Kong medical journal = Xianggang yi xue za zhi.
[42] K. Rentsch,et al. Ketamine-like effects after recreational use of methoxetamine. , 2012, Annals of emergency medicine.
[43] W. Buchwald,et al. Phencyclidine: Detection and measurement of toxic precursors and analogs in lllicit samples. , 1980, Journal of analytical toxicology.
[44] T. Litovitz,et al. Monitoring trends in dextromethorphan abuse using the National Poison Data System: 2000–2010 , 2011, Clinical toxicology.
[45] M. Schmutz,et al. 1 – Selfotel (CGS19755) , 1997 .
[46] A. Shulgin. Drugs of abuse in the future. , 1975, Clinical toxicology.
[47] Marion Kee,et al. Analysis , 2004, Machine Translation.
[48] G. Bigelow,et al. Guidelines and methodological reviews concerning drug abuse liability assessment. , 2003, Drug and alcohol dependence.
[49] S. Nordt. "DXM": A New Drug of Abuse? , 1998, Annals of emergency medicine.
[50] E. Lear. INTRAVENOUS ANESTHESIA ..... a survey of newer agents , 1968, Anesthesia and analgesia.
[51] A. Giannini,et al. A case of phenylcyclohexylpyrrolidine (PHP) intoxication treated with physostigmine. , 1982, Journal of toxicology. Clinical toxicology.
[52] E. Domino,et al. Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man , 1965, Clinical pharmacology and therapeutics.
[53] K. Shahzad. Understanding mechanisms of Ketamine-induced human urinary tract damage , 2011 .
[54] J. Kamenka,et al. Conformational determination of phencyclidine derivatives for a structure activity correlation , 1979 .
[55] R. Gupta,et al. Phencyclidine: patterns seen in street drug analysis. , 1976, Clinical toxicology.
[56] P. Herrling,et al. List of Drugs in Development for Neurodegenerative Diseases , 2004, Neurodegenerative Diseases.
[57] T. Nabeshima,et al. Phencyclidine-induced discriminative stimulus is mediated via phencyclidine binding sites on the N-methyl-d-aspartate receptor-ion channel complex, not via sigma1 receptors , 2001, Behavioural Brain Research.
[58] G. Albers,et al. Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke. , 1999, Stroke.
[59] K. Bailey. Identification of a street drug as N-ethyl-1-phenylcyclohexylamine, a phencyclidine analog. , 1978, Journal of pharmaceutical sciences.
[60] J. Casale,et al. The Characterization of 2-( 3-Methoxyphenyl )-2-( ethylamino ) cyclohexanone ( Methoxetamine ) , 2012 .
[61] H. Hirbec,et al. Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor. , 2006, CNS drug reviews.
[62] J. Meyer,et al. A NEW DRUG CAUSING SYMPTOMS OF SENSORY DEPRIVATION Neurological, Electroencephalographic and Pharmalogical Effects of Sernyl , 1959 .
[63] R. Degkwitz. [DEXTROMETHORPHAN (ROMILAR) AS AN INTOXICATING AGENT]. , 1964, Der Nervenarzt.
[64] Yueh-Ching Chou,et al. Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan , 1999, Brain Research.
[65] M. Lazdunski,et al. CHEMICAL SYNTHESIS AND MOLECULAR PHARMACOLOGY OF HYDROXYLATED 1-(1-PHENYLCYCLOHEXYL)PIPERIDINE DERIVATIVES , 1982 .
[66] E. Domino. Chemical dissociation of human awareness: focus on non-competitive NMDA receptor antagonists , 1992, Journal of psychopharmacology.
[67] K. Jansen. Ketamine: Dreams and Realities , 2004 .
[68] J. Woods,et al. Discriminative stimulus effects of narcotics: evidence for multiple receptor-mediated actions. , 1981, Life sciences.
[69] R. Schwartz. Adolescent Abuse of Dextromethorphan , 2005, Clinical pediatrics.
[70] L. Dods. Observations on certain aspects of the cyclic vomiting syndrome. , 1935 .
[71] Derek Partridge,et al. The Soft Machine , 2011 .
[72] Andrew Grace. The Hive , 2015 .
[73] F. Vollenweider,et al. Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV) , 2010, PloS one.
[74] New street analogs of phencyclidine , 1992 .
[75] A C Moffat,et al. Drugs of abuse. , 2000, Science & justice : journal of the Forensic Science Society.
[76] P. Dargan,et al. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine , 2012, European Journal of Clinical Pharmacology.
[77] Siegel Rk. Phencyclidine and ketamine intoxication: a study of four populations of recreational users. , 1978 .
[78] J. Smialek,et al. Cyclohexamine (“Rocket Fuel”)-Phencyclidine's Potent Analog , 1979 .
[79] R. Monastero,et al. Visual hallucinations and agitation in Alzheimer’s disease due to memantine: report of three cases , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[80] A. Andrews. UNITED STATES COURT OF APPEALS , 1998 .
[81] Y. Yoo,et al. A fatality due to injection of tiletamine and zolazepam. , 2000, Journal of analytical toxicology.
[82] D. MacLean,et al. Illicit synthesis of phencyclidine (PCP) and several of its analogs. , 1976, Clinical toxicology.
[83] R. Petersen,et al. Phencyclidine: an overview. , 1978, NIDA research monograph.
[84] P. Dargan,et al. Methoxetamine associated reversible cerebellar toxicity: Three cases with analytical confirmation , 2012, Clinical toxicology.
[85] K. Jellinger. Ionotropic Glutamate Receptors as Therapeutic Targets , 2004 .
[86] G. Rosenbaum,et al. Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.
[87] A. General,et al. UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT , 2015 .
[88] H. Sandler,et al. Fatal intoxication by dextromethorphan: a report on two cases. , 1988, Forensic science international.
[89] J. Wallach,et al. From the street to the laboratory: analytical profiles of methoxetamine, 3-methoxyeticyclidine and 3-methoxyphencyclidine and their determination in three biological matrices. , 2013, Journal of analytical toxicology.
[90] A. Kalir,et al. 1-Phenycycloalkylamine derivatives. II. Synthesis and pharmacological activity. , 1969, Journal of medicinal chemistry.
[91] E. Domino. Taming the Ketamine Tiger , 2010, Anesthesiology.
[92] J. Inciardi,et al. A critical review of pentazocine abuse. , 1971, HSMHA health reports.
[93] R. Tampi,et al. A systematic review of off-label uses of memantine for psychiatric disorders , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[94] D. Lodge,et al. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate , 1983, British journal of pharmacology.
[95] R. Deluca,et al. A fatality related to the veterinary anesthetic telazol. , 1999, Journal of analytical toxicology.
[96] M. Rogawski,et al. Synthesis and anticonvulsant activity of 1-phenylcyclohexylamine analogues. , 1990, Journal of Medicinal Chemistry.
[97] A. Giannini,et al. Treatment of phenylcyclohexylpyrrolidine (PHP) psychosis with haloperidol. , 1985, Journal of toxicology. Clinical toxicology.
[98] Emcdda. Annual Report 2009: the state of the drugs problem in Europe , 2009 .
[99] List of Drugs in Development for Neurodegenerative Diseases , 2007, Neurodegenerative Diseases.
[100] K. Rice,et al. The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: evidence for N-methyl-D-aspartate-coupled and dopamine reuptake carrier-associated phencyclidine binding sites. , 1989, Molecular pharmacology.
[101] J. Ballinger,et al. GLC Quantitation of 1-Piperidinocyclohexanecarbonitrile (PCC) in Illicit Phencyclidine (PCP) , 1979 .
[102] M. Lazdunski,et al. Biochemical properties of the brain phencyclidine receptor. , 1982, European journal of pharmacology.
[103] E. Domino. History and pharmacology of PCP and PCP-related analogs. , 1980, Journal of psychedelic drugs.
[104] C. Haertzen,et al. Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. , 1986, The Journal of pharmacology and experimental therapeutics.
[105] E. Sellers,et al. Assessing Abuse Liability During Drug Development: Changing Standards and Expectations , 2008, Clinical pharmacology and therapeutics.
[106] F. Greifenstein,et al. A STUDY OF A 1‐ARYL CYCLO HEXYL AMINE FOR ANESTHESIA* , 1958, Anesthesia and analgesia.
[107] Alan D. Woolf,et al. Abuse of Telazol: An Animal Tranquilizer , 2001, Journal of toxicology. Clinical toxicology.
[108] C. E. Reier. Ketamine--"dissociative agent" or hallucinogen? , 1971, The New England journal of medicine.